Ryzumvi Solution/ Drops
Product Images NDC 83368-075

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ryzumvi (NDC 83368-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oyster Point Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dosage And Administration Twist Top Figure (Image 02)

Chemical structure of phentolamine mesylate depicted as a molecular diagram showing the arrangement of atoms and bonds associated with this active pharmaceutical ingredient.*

FDA Label Image

Chemical Structure (Image 01)

Packaging label for Ryzumvi (phentolamine ophthalmic solution) 0.75%, an ophthalmic solution for topical use in the eyes. The label states it is sterile and includes 6 pouches containing 5 single-patient-use vials each. The labeler is Oyster Point Pharma, Inc. The label design features green, blue, and white color blocks with the Rx only designation and a barcode.*

FDA Label Image

Figure 2. Percentage Of Subjects With Study Eyes Returning To ≤ 0.2 Mm From Baseline Pupil Diameter By Time Point In The Mira-2 And Mira-3 Trials (Image 07)

Two bar charts titled MIRA-2 and MIRA-3. Each chart presents the percentage of subjects showing a response at multiple time points post-treatment in hours (0 to 24). The charts compare Ryzumvi Ophthalmic Solution 10 mg/mL with placebo and RU-4321 study eye groups, illustrating response rates over time.*

FDA Label Image

Figure 3: Pupil Dilation By Time Point With Phenylephrine As Mydriatic Agent In Mira-2 And Mira-3 Trials (mitt Population) (Image 08)

Two line graphs displaying pharmacokinetic data labeled MR8-2 and MR8-3, respectively. Both graphs plot phentolamine concentration (ng/mL) on the y-axis against time post-treatment (hours) on the x-axis, showing comparisons of phentolamine mesylate 10 mg/mL treatment with placebo over a 24-hour period.*

FDA Label Image

Figure 4: Pupil Dilation By Time Point With Tropicamide Or Paremyd As Mydriatic Agent In Mira-2 And Mira-3 Trials (mitt Population) (Image 09)

Two plots showing mean intraocular pressure (IOP) over time post-treatment in hours, comparing Ryzumvi ophthalmic solution 10 mg/mL to placebo in two separate studies labeled MPA-2 and MPA-3. Each graph illustrates IOP trends for treated and placebo groups across time points up to 24 hours.*

FDA Label Image

Ryzumvi (phentolamine Ophthalmic Solution) 0.75% Carton Label (Image 03)

Two bar graphs titled MIRA-2 and MIRA-3 display the percentage of subjects over time post treatment (hours) comparing placebo study eye, RYZUMVI study eye, and RYZUMVI fellow eye. Percentages are shown on the y-axis and time on the x-axis, illustrating treatment response rates with significant differences marked.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.